BASEL, Switzerland — January 13, 2015. Roche, Meiji Seika Pharma, and Fedora announced a license agreement for developing and commercializing OP0595, a β-lactamase inhibitor in Phase I clinical trials. Roche obtained worldwide rights except in Japan, where Meiji retains sole commercialization rights.
There is an urgent need for new antibiotics able to combat the increasing resistance to antibiotics that is being seen worldwide.Janet Hammond, Head of Infectious Diseases, Roche
Under the agreement, Meiji and Fedora will receive upfront payments plus development, regulatory, and sales milestone payments totaling up to $750 million, plus tiered royalties on product sales.
The properties of OP0595 and its ability to be combined with new or existing β-lactam antibiotics promise a significant advance.Christopher G. Micetich, CEO, Fedora Pharmaceuticals
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
